HUDDINGE, Sweden--(BUSINESS WIRE)--Regulatory News: “The pharmacokinetic interaction between the investigational NS3-4A HCV protease inhibitor TMC435 and methadone”
Medivir AB (OMX: MVIR), a research-based speciality pharmaceutical company focused on infectious diseases, today announces that four abstracts related to its once daily (QD), oral investigational hepatitis C drug TMC435 have been accepted for presentation at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place from November 4-8 in San Francisco, USA.
